Welcome to our dedicated page for 2Seventy Bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2Seventy Bio stock.
2seventy bio, Inc. (Nasdaq: TSVT) is an immuno-oncology cell therapy company centered on Abecma (idecabtagene vicleucel; ide-cel), a BCMA-directed autologous CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma after at least two prior lines of therapy. The TSVT news stream features company announcements that combine scientific, commercial, and corporate developments related to this program and its broader collaboration with Bristol Myers Squibb (BMS).
Investors and observers following TSVT news will find regular updates on Abecma’s U.S. commercial performance, including quarterly and full-year revenues as reported by BMS, trends in demand such as patients undergoing apheresis, and commentary on Abecma’s role in the multiple myeloma treatment landscape. Releases also discuss regulatory milestones, label expansions into earlier-line settings, and decisions around clinical studies such as the discontinuation of enrollment in the Phase 3 KarMMa-9 trial in newly diagnosed multiple myeloma.
Corporate and financial news for 2seventy bio includes quarterly earnings reports, changes in operating expenses, net cash spend, and cash, cash equivalents, and marketable securities. The company has reported transactions such as the sale of its oncology R&D business to Regeneron and the sale of its Hemophilia A program and gene editing technology to Novo Nordisk, which it characterizes as supporting an exclusive focus on Abecma. Conference participation and investor events, including healthcare conferences and fireside chats, are also covered in TSVT news items.
A key current theme in 2seventy bio’s news is its definitive merger agreement with Bristol Myers Squibb. News releases describe the agreed all-cash acquisition, the tender offer structure, the Hart-Scott-Rodino review process, and the expectation that, following completion of the transaction and a second-step merger, 2seventy bio’s common stock will no longer trade on Nasdaq. For readers tracking TSVT, the news page provides an evolving record of Abecma’s commercial trajectory, strategic partnerships, and the company’s pending transition into BMS.
2seventy bio (Nasdaq: TSVT) reported its Q3 2021 financial results, posting total revenues of $19.3 million, a slight increase from $18.4 million in Q3 2020. The company has accepted its first IND for SC-DARIC33 to treat acute myeloid leukemia, now enrolling patients in a Phase 1 study. Research and development expenses decreased to $61.1 million from $72.3 million year-over-year. Despite a net loss of $60 million, 2seventy remains optimistic about its pipeline and partnerships, particularly with Bristol Myers Squibb for ABECMA, which generated $67 million in revenue.
2seventy bio, Inc. (NASDAQ: TSVT) will participate in a fireside chat at the 5th Annual Cowen IO Next Summit on November 15 at 1:15 PM ET. A webcast will be available for 30 days post-event via their investor relations website. The company is dedicated to developing groundbreaking immuno-oncology therapies, aiming to combat cancer more effectively. Their mission focuses on translating research into actionable therapies, particularly for hematologic malignancies. For more details, visit www.2seventybio.com.
2seventy bio (NASDAQ: TSVT) has announced that it will present data from its pipeline of oncology cell therapies at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. Highlights include new pre-clinical data on SC-DARIC33, a CD33-targeting CAR T therapy for acute myeloid leukemia, and updated results from the Phase I CRB-402 study of bb21217, a BCMA-directed CAR T therapy for multiple myeloma. Both presentations aim to showcase advancements in treatment options for hematologic malignancies.
2seventy bio officially launches as an independent, publicly traded company on Nasdaq under the symbol TSVT on November 5. The company, a spin-off from bluebird bio, presents a robust pipeline in immuno-oncology cell therapies, including the recently approved ABECMA for multiple myeloma, which garnered $67 million in its first full quarter. The company is backed by approximately $442 million in cash, ensuring operational funding into 2023. With plans for innovative clinical studies in hematologic and solid tumors, 2seventy aims to transform cancer treatment.